Get the Stockscreener App
281.00
0.31%
-0.675
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $281.00, with a volume of 799.27K.
It is down -0.31% in the last 24 hours and up +8.96% over the past month.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$281.67
Open:
$279.8
24h Volume:
799.27K
Relative Volume:
0.46
Market Cap:
$54.67B
Revenue:
$328.68B
Net Income/Loss:
$2.55B
P/E Ratio:
21.56
EPS:
13.0349
Net Cash Flow:
$1.56B
1W Performance:
+2.45%
1M Performance:
+8.96%
6M Performance:
-19.84%
1Y Performance:
-4.99%
1-Day Range:
$274.71
$281.75
1-Week Range:
$270.64
$284.93
52-Week Range:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
280.97 | 54.80B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
777.67 | 94.25B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
225.79 | 52.43B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
81.19 | 9.26B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.26 | 1.15B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-22-26 | Upgrade | Jefferies | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Flagship logistics upgrade: Cencora’s Fusion Center platform scales real-time pharma visibility - AD HOC NEWS
Cencora Inc. Stock (US15135B1017): Valuation metrics in focus after steady share price climb - AD HOC NEWS
Is Cencora stock underperforming the Nasdaq? - MSN
Cencora Inc Stock (US03073E1055): Analyst Rating In Focus After Barclays Cuts Target - AD HOC NEWS
The Profit Margin Climb Cencora Stock Bears Keep Missing - Trefis
Cencora Drug Distribution Story Gains Healthcare Market Attention - Kalkine Media
Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential - Yahoo Finance
Barclays Cuts Cencora Price Target to $350 From $425, Maintains Overweight Rating - marketscreener.com
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Central Garden & Pet stock (US15135B1017): earnings momentum and pet-care demand in focus - AD HOC NEWS
What Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders - simplywall.st
Cencora hits 52-week low after guidance cut - MSN
Is Cencora Stock Underperforming the Nasdaq? - Barchart.com
Cencora, Inc. (COR) Stock Analysis: Strong Buy Ratings and 29.74% Potential Upside Spark Investor Interest - DirectorsTalk Interviews
A Look At Cencora (COR) Valuation After 2026 Guidance Update And New CAR T Distribution Deal - simplywall.st
Cencora shares fall 2% on second quarter earnings miss - Investing.com
Deals tracker: Tennessee senior care operator spends $50M for 5 facilities - Modern Healthcare
Cencora's Specialty Supply Chain: Where COR's Growth Is Headed - Yahoo Finance
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know - Yahoo Finance
Cencora Q2 FY2026 slides: strategic moves amid revenue miss - Investing.com
Earnings Flash (COR) Cencora, Inc. Reports Q2 Revenue $78.36B, vs. FactSet Est of $81.09B - marketscreener.com
Earnings Flash (COR) Cencora, Inc. Posts Q2 Adjusted EPS $4.75 per Share, vs. FactSet Est of $4.82 - marketscreener.com
Cencora shares fall 2% on second quarter earnings miss By Investing.com - Investing.com Nigeria
Cencora cuts revenue growth forecast on slower US sales - marketscreener.com
Earnings call transcript: Cencora Inc. Q2 2026 misses estimates, stock drops - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc.COR - PR Newswire
WCG Wealth Advisors LLC Purchases New Position in Cencora, Inc. $COR - MarketBeat
Cencora Inc. stock (US15135B1017): shares steady as guidance raised and buyback expanded - AD HOC NEWS
Cencora shareholders elect directors and approve key proposals at annual meeting - Investing.com
Cencora (COR) Has a Specialty-Distribution Moat That Looks Stronger Than Its Thin Margins Suggest - AlphaStreet
Cencora Inc. stock (US15135B1017): new Kite CAR T-cell distribution deal highlights specialty focus - AD HOC NEWS
Cencora-Kite Agreement Signals CGT Commercialization Shift - Pharmaceutical Commerce
Cencora Inc stock (US03073E1055): shares steady ahead of next earnings after recent legal headlines - AD HOC NEWS
Billions spent, a new CFO, and a bold vision: Cencora is transforming healthcare from Conshohocken - MSN
Is Cencora’s New CFO, $2 Billion Buyback, and Lawsuit Trio Altering The Investment Case For Cencora (COR)? - Yahoo Finance
Cencora Inc. stock outperforms competitors despite losses on the day - MarketWatch
Cencora Inc. stock (US15135B1017): shares ease while investors digest new corporate responsibility r - AD HOC NEWS
Cencora, Inc. (COR) Stock Analysis: Evaluating a 32% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Cencora Inc. stock (US15135B1017): steady trading as NYSE healthcare distributor holds fiscal 2026 E - AD HOC NEWS
Insider Spends US$1.1m Buying More Shares In Cencora - simplywall.st
Cencora Appoints Eva Boratto as CFO and Reaffirms 2026 Financial Guidance - Minichart
Cencora appoints Eva Boratto as CFO, reaffirms guidance - MSN
Cencora Inc. stock (US15135B1017): new CFO appointment and 2026 EPS guidance reaffirmed - AD HOC NEWS
Assessing Cencora (COR) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st
Cencora, Inc. (COR) Appoints New CFO and Reaffirms Financial Gui - GuruFocus
Eva C. Boratto named Cencora Executive VP & CFO as James F. Cleary to retire - TradingView
Cencora (NYSE: COR) hires new CFO Eva Boratto and reaffirms 2026 and long-term EPS targets - Stock Titan
Insider Buying: Dermot Durcan Acquires Shares of Cencora Inc (CO - GuruFocus
Cencora director D. Mark Durcan buys $1.07m in stock By Investing.com - Investing.com Canada
Cencora director D. Mark Durcan buys $1.07m in stock - Investing.com
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):